ABSTRACT Introduction: The rising global prevalence and potential harms of cannabis use among adolescents and young adults are cause for concern. This systematic review focuses on the Arab world, compiling research on cannabis consumption among school and university students, where use has significantly increased but remains inadequately evaluated. Methods: The review was registered in PROSPERO (CRD42021285103). Following PRISMA 2020 guidelines, two researchers searched PubMed, Embase, Scopus, and PsycInfo from inception to 9 May 2024, with no filters or language restrictions. Grey literature was identified through structured searches in Google Scholar and ProQuest Dissertations & Theses Global on 30 August 2024, as well as through reference list...

Abstract Cannabis use for sleep is increasingly prevalent, yet its effects on sleep architecture remain unclear. This systematic review and meta-analysis examined polysomnographic evidence on cannabis’ impact on sleep parameters. Eighteen studies were identified, with nine suitable for meta-analysis. Findings indicate that cannabis administration does not consistently alter sleep duration, latency, wake time, efficiency, or sleep staging. While early studies suggested reductions in rapid eye movement sleep, these were primarily based on small-scale trials with high tetrahydrocannabinol doses and significant methodological limitations. More recent studies using larger samples and lower therapeutic doses of tetrahydrocannabinol have reported mixed (and often no) evidence of rapid eye...

Abstract Background Cannabis is increasingly recommended to treat female orgasmic disorder/difficulty (FOD/difficulty), a condition that affects up to 41% of women worldwide with no conventional medications. Aim To systematically review the existing literature on cannabis and its impact on female orgasm function. Methods A systematic review based on the PRISMA model evaluated the effects of cannabis on orgasm function in females with or without FOD/difficulty. Risk of bias was assessed for randomized and nonrandomized studies. Searches were conducted in PubMed, Google Scholar, Cochrane, and Embase. Outcomes Primary outcomes focused on the impact of cannabis on female orgasm function. Results Sixteen studies met inclusion criteria:...

Abstract Cannabis and its bioactive compounds, specifically tetrahydrocannabinol and cannabidiol, are rapidly growing in popularity for their therapeutic applications across a variety of medical specialties, including dentistry. This narrative review aims to explore the current and future applications of cannabinoids in dentistry and the therapeutic potential, problems, and ethical issues. Cannabinoids possess analgesic, anti-inflammatory, anxiolytic, and neuroprotective properties that may be beneficial in the treatment of orofacial neuropathic pain, temporomandibular joint disorders, myofascial pain dysfunction syndrome, bruxism, and obstructive sleep apnea. Despite their potential benefits, the integration of cannabinoids into dental practice is limited by the absence of standardized treatment regimens, insufficient high-quality clinical...

Abstract BackgroundAbrupt cessation of heavy cannabis use can cause a withdrawal syndrome characterised by irritability, anxiety, insomnia, reduced appetite and restlessness. Recent reports have also described people in whom cannabis withdrawal immediately preceded the acute onset of psychosis. AimsTo identify cases of psychosis associated with cannabis withdrawal. MethodWe completed a systematic review of the literature, which comprised case reports, case series and other studies. We also searched a large electronic database of psychiatric healthcare records. ResultsThe systematic review identified 44 individuals from 21 studies in whom cannabis withdrawal preceded the development of acute psychosis. In the health record study, we identified another 68 people,...

Please use this link to access this publication. Abstract Background Cannabis use in the general population is prevalent and is rising because of increased acceptance of its use, legalization in most US states, and perceived health benefits. Cannabis product potency has dramatically increased with higher delta-9-tetrahydrocannabinol content. Cannabis has documented antiemetic properties and cannabinoid pharmaceuticals are used in disorders like chemotherapy-induced nausea and vomiting. Purpose Forty to eighty percent of cyclic vomiting syndrome (CVS) patients use cannabis products, which reportedly reduce stress as well as nausea and vomiting. Cannabinoid hyperemesis syndrome (CHS) has a presentation similar to CVS, but is associated with longstanding, high...

Abstract Between 8 and 22% of lifetime cannabis users develop Cannabis Use Disorder (CUD). It is the most frequent reason for first-time drug-related treatment admissions in Europe. Many countries have general substance use treatment programs for individuals with cannabis use disorders. This study presents an updated overview of cannabis-specific treatment availability across Europe. Data on treatment programs in 27 EU member states, United Kingdom, Norway and Turkey was gathered. The study used a mixed-methods approach, combining (1) a quantitative survey among the National Focal Points of the European Drugs Agency (EUDA), (2) a qualitative analysis of “Drug Workbooks 2021” and ‘Treatment Workbooks 2020 and 2021’...

Abstract Neuropathic pain is a chronic disorder that arises from damaged or malfunctioning nerves. Hypersensitivity to stimuli, also known as hyperalgesia, can cause a person to experience pain from non-painful stimuli, termed allodynia. Cannabis-based medicines (CBMs) may provide new treatment options to manage neuropathic pain. A review of the relevant studies was conducted to evaluate the effectiveness of CBMs in treating neuropathic pain. Scientific literature was systematically searched from January 2003 to December 2024 using the Web of Science Core Collection, PubMed, and MEDLINE. A total of 22 randomized controlled trials (RCTs) were identified that considered the use of 1′,1′-dimethylheptyl-Δ8-tetrahydrocannabinol-11-oic acid (CT-3), Δ9-tetrahydrocannabinol (Δ9-THC),...

Please use this link to access this publication. Abstract Cannabis remains one of the most frequently misused substances among adolescents. As recreational cannabis has proliferated across the United States, cannabis-related emergency department visits have increased. Cannabis hyperemesis syndrome, a variant of cyclic vomiting syndrome, has emerged as a recognized but poorly understood complication of chronic cannabis use among a subset of individuals. Cannabis hyperemesis syndrome is characterized by repeated cycles of abdominal pain, nausea, and vomiting refractory to standard antiemetics, with users reporting the compulsive use of hot showers to mitigate symptoms. Treatment modalities include intravenous fluid and electrolyte repletion, topical application of capsaicin,...

Abstract Cannabis products are increasingly perceived and advertised as natural and safe treatments for a variety of conditions, including chronic non-cancer pain (CNCP). The number of prescriptions for medicinal cannabis (MC) currently averages >80 000 per month for >1 million Australians. Although over 800 different cannabis products are available to prescribe in Australia, only two are registered on the Australian Register of Therapeutic Goods and approved by the Therapeutic Goods Administration for specific clinical indications. Using treatment for CNCP as an example, evidence of efficacy across nine systematic reviews was inconsistent and/or of low quality and, with the exception of neuropathic pain, was unable to...